Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Seoyoung | - |
dc.contributor.author | Jeon, Sang Won | - |
dc.contributor.author | Ko, Young-Hoon | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Han, Changsu | - |
dc.date.accessioned | 2021-09-03T10:13:55Z | - |
dc.date.available | 2021-09-03T10:13:55Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-02 | - |
dc.identifier.issn | 0271-0749 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84719 | - |
dc.description.abstract | Purpose/Background: Brexpiprazole was approved for adjunctive treatment of major depressive disorder (MDD) in 2015. Because only a small number of randomized controlled trials have investigated the use of brexpiprazole in MDD, we performed a meta-analysis. Methods/Procedures: We systematically searched literatures in PubMed, Cochrane Library database, EMBASE, Google Scholar, and clinicaltrials.gov up to January 2016. The primary efficacy measure was the mean change in total Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline. Secondary efficacy measures were the mean change in total Hamilton Rating Scale for Depression (17 items) score from baseline and the response (>= 50% reduction in MADRS total score) and remission (MADRS total score <= 10 with >= 50% reduction) rates. Findings/Results: Four studies fulfilled the inclusion criteria and were included in the analysis. Brexpiprazole showed superior efficacy over placebo with effect sizes (mean differences) of -1.76 (95% confidence interval [CI], -2.45 to -1.07) for MADRS and -1.21 (95% CI, -1.71 to -0.72) for the 17-item Hamilton Rating Scale for Depression. The risk ratios for response and remission were 1.57 (95% CI, 1.29-1.91) and 1.55 (95% CI, 1.22-1.96), respectively. The incidences of discontinuation due to adverse events, akathisia, and weight increase were higher in the brexpiprazole group than in the placebo group, with risk ratios of 3.44 (95% CI, 1.52-7.80), 3.39 (95% CI, 2.08-5.51), and 4.36 (95% CI, 2.45-7.77), respectively, and the incidence of akathisia was related to the brexpiprazole dose. Implications/Conclusions: Although our results suggest that brexpiprazole could be an effective adjunctive agent for MDD, they should be cautiously translated into clinical practice because the meta-analysis was based on only a handful of randomized controlled trials. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | DOPAMINE ACTIVITY MODULATOR | - |
dc.subject | SEROTONIN 5-HT1A RECEPTORS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | PSYCHIATRIC-DISORDERS | - |
dc.subject | INADEQUATE RESPONSE | - |
dc.subject | ANTIDEPRESSANT | - |
dc.subject | ARIPIPRAZOLE | - |
dc.subject | AUGMENTATION | - |
dc.subject | TOLERABILITY | - |
dc.subject | EFFICACY | - |
dc.title | Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ko, Young-Hoon | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1097/JCP.0000000000000622 | - |
dc.identifier.scopusid | 2-s2.0-85004011508 | - |
dc.identifier.wosid | 000391838500011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, v.37, no.1, pp.46 - 53 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.volume | 37 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 46 | - |
dc.citation.endPage | 53 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | DOPAMINE ACTIVITY MODULATOR | - |
dc.subject.keywordPlus | SEROTONIN 5-HT1A RECEPTORS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PSYCHIATRIC-DISORDERS | - |
dc.subject.keywordPlus | INADEQUATE RESPONSE | - |
dc.subject.keywordPlus | ANTIDEPRESSANT | - |
dc.subject.keywordPlus | ARIPIPRAZOLE | - |
dc.subject.keywordPlus | AUGMENTATION | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | brexpiprazole | - |
dc.subject.keywordAuthor | OPC-34712 | - |
dc.subject.keywordAuthor | major depressive disorder | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | tolerability | - |
dc.subject.keywordAuthor | meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.